However, pancreatic cancer has remained resistant to PD-1/PD-L1 inhibition, apart from a rare population of pancreatic cancers with high microsatellite instability (MSI-H) representing less than 1% of all patients [6]. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.